PhaRmacogenetics Of the Glycemic Response to SGLT2 Inhibitors (PROGRESS)
What is PROGRESS?
We are studying how genetics may influence the way the diabetes medication, dapagliflozin, works in the body.
What will happen at PROGRESS study visits?
- If you do not have recent bloodwork results, come in for a screening visit where a brief blood draw will be performed
- If you have diabetes, stop your home diabetes medication for 5 days before your visit
- At each visit
- Height and weight measurements
- Glucose checks
- Blood draws
- Urine collections
- Take the study drug daily for 5 days at home and once during the second visit
Interested in joining?
Contact our research coordinator Rachel Huynh today at (617) 726 – 6537 or send us an email at mghprogress@mgb.org